Trial Profile
CRYSTAL Study: A Multi-Center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2020
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms CRYSTAL
- Sponsors Micell Technologies
- 03 Sep 2020 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.
- 03 Sep 2020 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
- 03 Sep 2020 Planned initiation date changed from 31 Dec 2020 to 31 Dec 2021.